Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

President Trump’s executive order aims to bring down drug prices while optimizing IP protections, and Congress should pass ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Stocks were boosted in May by easing trade tensions, solid corporate earnings and signs the U.S. economy remains resilient ...

Swiss President Karin Keller-Sutter will visit pharma powerhouse Ireland tomorrow for high-level talks ahead of President ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief the plan would be hard to implement Drug prices are expected to decline ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...